The hypereosinophilic syndromes: still more heterogeneity.
In 1968, the term hypereosinophilic syndromes (HES) was coined to refer to a spectrum of eosinophil-associated diseases presumed to be caused by an underlying immunological pathology. In the 1990s, the identification of an HES subset with T lymphocyte clonality and production of cytokines, particularly IL-5, validated this concept. Then, in 2002, imatinib mesylate, which was introduced for the treatment of chronic myelogenous leukemia, effectively controlled another subgroup of HES patients. Imatinib's target is a novel constitutively-active kinase. Most imatinib-responsive HES patients show an increased number of bone marrow mast cells and elevated serum tryptase; mast cells, lymphocytes and neutrophils express the novel kinase. This new information critically modifies our view of HES and indicates that several cell lines are altered and likely to contribute to HES pathophysiology.
Gleich
Gerald J
GJ
Department of Dermatology, University of Utah Health Sciences Center, 4B454 School of Medicine, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA. gerald.gleich@hsc.utah.edu
Leiferman
Kristin M
KM
D001549:Benzamides; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy; D000068877:Imatinib Mesylate; D008407:Mast Cells / Q000187:drug effects; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate